Laurie H. Sehn

Laurie H. Sehn, MD, MPH, FRCPC is a Medical Oncologist at BC Cancer Vancouver Centre and Clinical Professor at the University of British Columbia, where she is recognized internationally as one of the leading experts in lymphoma management and clinical trial design. She is best known for her pivotal contributions to the GALLIUM trial — a landmark phase III randomized study (published in NEJM 2017) that compared obinutuzumab-based chemoimmunotherapy versus rituximab-based chemoimmunotherapy in previously untreated follicular lymphoma. GALLIUM demonstrated significantly improved progression-free survival with obinutuzumab, establishing it as a superior anti-CD20 backbone in follicular lymphoma and contributing to its regulatory approvals in multiple jurisdictions. Dr. Sehn has also made foundational contributions to the optimization of R-CHOP therapy in DLBCL, leading analyses that helped characterize which patient subgroups derive the greatest benefit from standard and intensified regimens. She has led or co-led numerous international cooperative group trials in B-cell NHL through GELA/LYSA and the Canadian Cancer Trials Group (CCTG), and is a senior faculty member of the International Prognostic Index (IPI) and FLIPI validation consortia. Dr. Sehn has authored more than 200 peer-reviewed publications and serves on advisory boards for ASCO, ESMO, and major lymphoma cooperative groups worldwide.